Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis
Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…
CertaraJuly 16, 2026
When to conduct hepatic impairment studies and when modeling may be enough
How to decide if a hepatic impairment study is required, choose the right study design,…
Zoe BarterJuly 13, 2026
AI, HTA, and the future of access: Inside the 12th annual Kraków HTA symposium
Explore key insights from the 12th Annual Kraków HTA Symposium covering HTA, reimbursement policy, AI…
Malwina Holownia, PhDJuly 8, 2026
Dosimetry for radiopharmaceutical therapy: From measurement to dose justification
Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…
Hunter Stephens, PhDJuly 7, 2026
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors
Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…
CertaraJuly 1, 2026
Enhancing clinical trials with real-world evidence in pregnancy research
Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…
Alekhya Lavu, PhD, PharmDJune 26, 2026
